drugset / Trial / NCT00606359
Immunogenicity of the Inactivated Split-Virion Influenza Vaccine in Renal Transplant Subjects
RandomizedParallel-groupOpen-labelPrevention
Summary
Primary Objective: To describe the immunogenicity of an injection of the investigational inactivated, split-virion influenza vaccine 21 days after vaccination in 18 to 60 years old renal transplant subjects identified as non-responder to previous vaccination with the IM reference vaccine (Vaxigrip®). Secondary Objective: To describe the safety of an injection of the investigational inactivated, split-virion influenza vaccine in 18 to 60 years old renal transplant subjects identified as non-responder to previous vaccination with the IM reference vaccine
Timeline
- Start
- 2007-11
- Primary completion
- 2008-02
- Completion
- 2008-06
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Inactivated, Split-Virion Influenza Virus | Vaccine | 0.1 ml | Intramuscular |
| Comparator | Inactivated, Split-Virion Influenza Virus | Vaccine | 0.5 ml | Intramuscular |